Đang chuẩn bị liên kết để tải về tài liệu:
CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

Adjuvant therapy improves the prognosis of stage II & III colon cancer patients. Unfortunately, most patients do not benefit from this treatment. PePITA (NCT00994864) is a prospective, multicenter, non-randomized study whose primary objective is to predict the outcome of adjuvant therapy in colon cancer. | CTCs as a prognostic and predictive biomarker for stage II III Colon Cancer A companion study to the PePiTA trial

TÀI LIỆU LIÊN QUAN

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer

Đánh giá các chỉ số giải phẫu C1, C2 trên phục vụ cho phẫu thuật CTCS cổ cao

Can Tho city socio economic and environmental transformation based on sustainability: Situation and solution

The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer

Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients

Conventional Computed Tomographic Calcium Scoring vs full chest CTCS for lung cancer screening: A cost-effectiveness analysis

The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma

Post-therapeutic circulating tumor cell-associated white blood cell clusters predict poor survival in patients with advanced driver gene-negative non-small cell lung cancer

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: A companion study to the PePiTA trial